Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

NCT03586999 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Peripheral T Cell Lymphoma

Interventions

DRUG: Nivolumab
DRUG: Etoposide
DRUG: Prednisolone
DRUG: Oncovin
DRUG: Cyclophosphamide
DRUG: Hydroxydaunorubicin

Sponsor

University of Colorado, Denver

Collaborators

[object Object]